Banner displaying the Vital Tones logo and company name.

RESEARCH

DBSS Research & Evidence

Vital Tones develops Deep Brain Sound Stimulation (DBSS), a non-invasive auditory neuromodulation technology designed to interact with specific brain and body systems through precisely structured sound. Developed over more than twelve years, DBSS has been applied across neurological, psychological, cognitive, and physical conditions, with research ranging from large-scale observational studies to MRI-documented case reports.

 

Below is an overview of published, preprint, and ongoing DBSS research covering neurological, psychological, cognitive, and physical applications.

 

Published and Preprint Research

Our research portfolio includes peer-reviewed work, publicly available preprints, case reports, and ongoing studies. Together, they document the developing scope of DBSS across neurological, psychological, and physical applications. Click on any study title to access the full report.

 

Peer-Reviewed Publication:

 

 

Preprints (Under Review for Publication):

 

Joint and Ligament Recovery — MRI-Documented Case

 

  • Audio Brainwave Treatment Restores Chronic ACL–PCL Ruptures: MRI-Verified Case Report
    This MRI-verified case highlights a promising direction for DBSS in chronic physical injury. A patient with long-standing ACL–PCL ruptures showed structural improvement following a Vital Tones sound-based stimulation protocol, documented by pre- and post-treatment MRI. The findings support further investigation of DBSS in ligament and joint regeneration.
    • Evidence: Pre- and post-MRI scans showing improvement
    • Safety: No side effects reported

       We are now collecting more MRI cases to prepare a larger, multi-patient clinical report.

       If you're interested in contributing to this study, please refer to the full report for participation information.

 

 

Spinal Disc Recovery — MRI-Documented Case

 

    • Evidence: Pre- and post-MRI reports showing resolution
    • Safety: No side effects reported

       If researchers are interested in conducting replication studies, they are welcome to contact us..

 

 

Core DBSS Technology and Overview

 

    • Study Scope: Over 6,400 users across 50 therapy applications
    • Safety: Minimal adverse effects
    • Reported Benefits: Cognitive, emotional, and motor improvements across conditions such as anxiety, depression, ADHD, Parkinson’s disease, and PTSD

 

Neurological and Psychological Disorders

 

    • Average self-reported change: 50% improvement in mood regulation

 

    • Average self-reported change: 65% improvement in mood stability

 

    • Average self-reported change: 65% reduction in anxiety symptoms

 

    • Average self-reported change: 50% improvement reported for DTD, and 80% for PTSD in symptom reduction

 

    • Average self-reported change: 57% improvement in ADHD symptoms, including attention and hyperactivity

 

    • Average self-reported change: 65% improvement in phonological awareness and reading fluency

 

    • Average self-reported change: 80% for Insomnia, 65% for Deep Sleep

 

    • Average self-reported change:50% reduction in OCD symptoms

 

    • Average self-reported change: 50% improvement in emotional regulation and impulsivity

 

 

Menstrual Pain Relief Using DBSS (Formal Study):

Following extensive pilot testing, a formal double-blind, placebo-controlled study of DBSS for primary dysmenorrhea will begin in October 2026, with approximately 174 participants. Participants will be assigned to either the DBSS intervention or a placebo sound condition, allowing the effect on menstrual pain to be evaluated under controlled conditions. The study will assess changes in pain intensity and the impact of dysmenorrhea on daily life.

 

Stuttering Fluency Improvement (Pilot Evaluation & R&D in Progress)

An 18-minute DBSS session for developmental stuttering is currently undergoing pilot evaluation and continued development. More than 20 adult male participants have tested the current version, with many reporting clear improvements in fluency, including reduced blocking, speaking effort, and physical tension.

 

Current R&D is focused particularly on improving responses in female stuttering, while further refinements may also improve outcomes in males. Formal independent evaluation with researchers specializing in stuttering is also being explored.

 

People outside the test group can try a free 3-minute trial. Those who notice a positive effect can subscribe for access to the current 18-minute session and future updates.

 

Glaucoma (Ongoing Single-Case Observation)

This case involves advanced glaucoma with approximately 90% vision loss in the left eye. The participant has undergone multiple ophthalmologic procedures, and no further conventional treatment options remain to address the existing vision loss. DBSS-based therapy has recently been initiated as a non-invasive exploratory approach. The planned protocol applies a stepwise SVZ-targeted neuromodulation strategy, with sequential focus on the optic nerve head and optic nerve, retinal ganglion cell layer (GCL), nerve fiber layer (NFL), and additional retinal structures.

 

Findings: Ongoing; early subjective signs of increased activity in the left eye reported

Safety: No adverse effects observed to date; monitoring ongoing

Limitations: Single-case observation; early-stage intervention

 

This exploratory case is being monitored to evaluate safety, feasibility, and potential biological activity in advanced glaucoma.

 

Nocturnal Epilepsy (Ongoing Single-Case Observation)

This case involves nocturnal seizure activity occurring exclusively during sleep, historically averaging 20–40 episodes per night, with no daytime events. During the ongoing DBSS observation period, reported nightly seizure frequency has decreased to two or fewer episodes, while existing medication has been maintained.

 

Findings: Marked reduction in reported nocturnal seizure frequency from 20–40 to ≤2 per night

Safety: No adverse effects have been reported in this case to date

Limitations: Single-case observation; long-term stability and medication-independent seizure control have not yet been established

 

The current objective is to determine whether seizure frequency can reach and remain at zero. Any future medication reduction would need to be gradual and medically supervised.

 

This exploratory case warrants continued observation to determine the durability and reproducibility of the response.

 

Severe Cerebral Palsy (Ongoing R&D Case Evaluation):

DBSS is currently being evaluated in a severe cerebral palsy case with profound motor impairment and high care dependency. Multiple protocols addressing motor, sensory, basal ganglia, thalamic, brainstem and spinal systems have been tested sequentially.

 

Early observations have included small increases in spontaneous hand movement, energy, smiling and laughter, while severe stiffness and major motor limitations remain largely unchanged. The case is continuing as an exploratory R&D program, with current work extending toward the white-matter pathways connecting these motor-control systems.

 

Hallux Rigidus / Advanced Big-Toe Joint Arthrosis (Ongoing R&D Case Evaluation):

Since February 2026, DBSS has been evaluated in a case of bilateral advanced hallux rigidus with severe cartilage and joint degeneration. Repeated pain-relieving injections had previously been required, and surgical fusion had been recommended.

 

Over the following months, pain and functional tolerance improved substantially. The participant remains highly active, including extensive walking, prolonged standing and occasional jogging. Footwear or heavy loading can still produce temporary discomfort, but symptoms have not returned to the previous persistent level.

 

This case is of particular research interest because spontaneous structural reversal of established advanced hallux rigidus is not part of its known natural history. Follow-up imaging is planned for around the end of 2026. Because the first MTP joint is small and anatomically well localized, it should allow a relatively direct comparison with pretreatment imaging.

 

Age-Related Macular Degeneration (Ongoing Single-Case Observation)

This case involves age-related macular degeneration (AMD) with progressive central vision loss. The 88-year-old participant presented with severely reduced visual acuity, historically limited to approximately 40–50% in the left eye and 5–10% in the right eye, with the right eye able to detect only light sources. Previous clinical management included anti-inflammatory and anti-VEGF injections, as well as intraocular lens optimization, each reaching usage limits without meaningful improvement. No conventional therapeutic options remained available.

 

During ongoing therapy, the participant has reported notable improvements in the functional vision of the right eye, including clearer perception of objects previously indistinguishable. Follow-up assessment using Optical Coherence Tomography (OCT) imaging is planned to evaluate retinal changes.

 

Findings: Subjective improvement in central visual perception, especially in the right eye

Safety: No adverse side effects reported

Limitations: Single-case observation; follow-up OCT pending

 

This exploratory case suggests potential non-invasive support for visual function in age-related macular degeneration, particularly in situations where pharmacologic and procedural options are exhausted.

 

 

Upcoming Research

Our research is continuously expanding, with additional studies nearing completion. Additional DBSS studies and reports are in development across several neurological, psychological, and physiological applications.

 

  • DBSS Research for Schizophrenia
  • DBSS Research for Restless Legs Syndrome (RLS)
  • DBSS Research for Migraine
  • DBSS Research for Fibromyalgia
  • DBSS Research for Stress

 

 

Future Directions and Exploratory Research

Current initiatives include:

 

  • Stage 2 Studies for Resistant Hypertension: Early results indicate potential support for managing blood pressure in cases unresponsive to medication. Further validation is in progress.

 

  • Exploratory Research on Brain-Immune Interaction: Investigations are underway to assess how sound-based neuromodulation may influence immune regulation, with the goal of identifying new pathways for treating immune-related disorders.

 

Research Collaboration

Vital Tones welcomes collaboration with researchers, laboratories and academic groups interested in investigating Deep Brain Sound Stimulation.

 

Potential projects may examine neural mechanisms, target specificity, brain and network responses, neuroplasticity, reproducibility, clinical applications, biological systems, or other questions relevant to the researcher's field.

 

Collaborations can range from exploratory and student research projects to neuroimaging, electrophysiology, computational analysis, clinical studies and other experimental approaches.

 

Vital Tones can provide the DBSS materials, technical background and protocol information relevant to an agreed research project.

 

Researchers interested in discussing a project or proposing another research direction are welcome to contact us.

 

 

 

Vital Tones - Connect with Us
Connect with Vital Tones

Return to Main Page

VITAL TONES 2015